676496-39-2Relevant academic research and scientific papers
NOVEL DGAT2 INHIBITORS
-
Page/Page column 16; 17, (2016/12/07)
The present invention provides compounds of the Formula below: [Formula should be inserted here] Where A, X, R, and R2-R3 are as described herein; methods of treating patients for hypertriglyceridemia and cardiovascular disease including dyslipidemia and
Thiazolo [5, 4-d] and their use as agrichemical Pyrrolopyrimidine
-
Paragraph 0115, (2016/10/08)
The present disclosure relates to thiazolo[5,4-d]pyrimidines and their use as agrochemicals and animal health products. In some embodiments, the disclosure relates to compounds of the formula (I-A) and of the formula (I-B):
Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1
Takeuchi, Kumiko,Holloway, William G.,McKinzie, Jamie H.,Suter, Todd M.,Statnick, Michael A.,Surface, Peggy L.,Emmerson, Paul J.,Thomas, Elizabeth M.,Siegel, Miles G.,Matt, James E.,Wolfe, Chad N.,Mitch, Charles H.
, p. 5349 - 5352 (2008/02/13)
A structurally unique and new class of opioid receptor antagonists (OpRAs) that bear no structural resemblance with morphine or endogenous opioid peptides has been discovered. A series of carboxamido-biaryl ethers were identified as potent receptor antagonists against mu, kappa and delta opioid receptors. The structure-activity relationship indicated para-substituted aryloxyaryl primary carboxamide bearing an amine tether on the distal phenyl ring was optimal for potent in vitro functional antagonism against three opioid receptor subtypes.
